Kaletra Tablets -Drug Insights, 2016

“Reasons to buy
• Evaluate the marketing status and exclusivity details of Kaletra Tablets to exploit opportunities for generic drug development opportunities.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Kaletra Tablets.
• API intelligence over Kaletra Tablets and gaining primary intelligence over Active Ingredients manufacturers across the globe.
• Understanding the chemical route of synthesis of Kaletra Tablets.
• Uncovering opportunities in the rapidly growing the US market
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
• Obtain sales forecast for currently marketed drug for to 2018
”

“Table of Contents

1. DelveInsight Report Introduction 
2. Kaletra Tablets Overview
2.1 Market Competition
2.3 Competitors in Development
3 Global Sales Assessment
3.1 Historical Sales of Kaletra Tablets
3.2 Forecasted Sales of Kaletra Tablets
4 Product Description
4.1 Mechanism of Action
4.2 Pharmacodynamic Properties 
4.3 Pharmacokinetic Properties
5 Marketed Details 
5.1 United States 
5.2 Europe
6 Patent Information 
6.1 Patent Numbers and Expiry Details
6.2 Patent and Exclusivity Expiry Assessment United States (US)
6.3 Patent Details
7 Route of Synthesis
8 Global API Manufacturers Assessment
8.1 The United States Drug Master File (US DMF)
8.2 The Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF)
8.3 The Active Pharmaceutical Ingredient (API) Manufacturers in China
8.4 The Active Pharmaceutical Ingredient (API) Manufacturers in India
9 Generic Players
10 The Pipeline Coverage
11 Clinical Trials Information
11.1 Clinical Trials by Zone
12 Company Profile
12.1 Company Summary
12.2 Company Financials
13 SWOT Analysis
14 References
15 Appendix
16 Methodology
17 Consulting Services
18 About DelveInsight
19 Contact Us 
20 Disclaimer
“
“List of Tables
• Table 1: Kaletra Tablets, Historical Global Sales (in million USD), 2016
• Table 2: Kaletra Tablets, Forecasted Global Sales (in million USD), 2016
• Table 3: Kaletra Tablets, Description
• Table 4: Kaletra Tablets, Marketed Details the United States (US)
• Table 5: Kaletra Tablets, Marketed Details the Europe (EU)
• Table 6: Kaletra Tablets, Patent/Exclusivity Expiry (Year), 2016
• Table 7: Kaletra Tablets, Patent Number Specific Patent Expiry (Year), 2016
• Table 8: Kaletra Tablets, Patent Details 
• Table 9: Kaletra Tablets, Route of Synthesis
• Table 10: Kaletra Tablets, the United States Drug Master File (US DMF), 2016
• Table 11: Kaletra Tablets, the Europe Active Substance Master File (ASMF), 2016
• Table 12: Kaletra Tablets, the API Manufacturers, China, 2016
• Table 13: Kaletra Tablets, the API Manufacturers, India, 2016
• Table 14: Kaletra Tablets, Generic Players, 2016
• Table 15: Kaletra Tablets, Pipeline Drug Details, 2016
• Table 16: Kaletra Tablets, Clinical Trials, 2016
• Table 17: Kaletra Tablets, Clinical Trials by Zone, 2016
• Table 18: Company Overview, 2016
• Table 19: Kaletra Tablets, SWOT Analysis, 2016
“
“List of Figures
• Figure 1: Kaletra Tablets, Historical Global Sales (in million USD), 2016
• Figure 2: Kaletra Tablets,  Forecasted Global Sales (in million USD), 2016
• Figure 3: Kaletra Tablets, Patent/Exclusivity Expiry (Year), 2016
• Figure 4: Kaletra Tablets, Patent Number Specific Patent Expiry (Year), 2016
• Figure 5: Kaletra Tablets, Route of synthesis
• Figure 6: Kaletra Tablets, the API Manufacturers by the US DMF Status (%), 2016
• Figure 7: Kaletra Tablets, the API Manufacturers by Region, 2016
• Figure 8: Kaletra Tablets, the API Manufacturers by Location/Countries, 2016
• Figure 9: Kaletra Tablets, Generic Players, 2016
• Figure 10: Kaletra Tablets, Clinical Trials by Zone (%), 2016
“